Gilead Sciences Highlights Trodelvy Lung Data, Long-Acting HIV Pipeline at RBC ConferenceMarketBeat • 05/24/26
FDA Grants Accelerated Approval to Gilead's Hepcludex® (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV)Business Wire • 05/22/26
Gilead Receives CHMP Positive Opinion for Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer for Patients Not Candidates for PD-(L)1 InhibitorsBusiness Wire • 05/22/26
New ASCO and EHA 2026 Data Demonstrate Gilead and Kite's Momentum Across Antibody-Drug Conjugates and Cell Therapy in OncologyBusiness Wire • 05/21/26
Gilead Sciences Completes Acquisition of Tubulis Further Strengthening Oncology PortfolioBusiness Wire • 05/21/26
Gilead Sciences and World Health Organization Expand Collaboration to Help Eliminate Visceral Leishmaniasis, a Fatal Parasitic DiseaseBusiness Wire • 05/21/26
Gilead Sciences, Inc. (GILD) Presents at RBC Capital Markets Global Healthcare Conference 2026 TranscriptSeeking Alpha • 05/19/26
Gilead Sciences Leans on HIV Growth as Deals Build Oncology, Inflammation PipelineMarketBeat • 05/17/26
Is It Worth Investing in Gilead (GILD) Based on Wall Street's Bullish Views?Zacks Investment Research • 05/13/26
Gilead to Present New Data Advancing Care in PBC and Viral Hepatitis at EASL 2026Business Wire • 05/13/26
Gilead Sciences, Inc. (GILD) Presents at Bank of America Global Healthcare Conference 2026 TranscriptSeeking Alpha • 05/13/26
Gilead (GILD) Q1 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks Investment Research • 05/07/26